Anaemia of cancer: impact on patient fatigue and long-term outcome.
Anaemia is the most common haematological abnormality encountered by cancer patients. A large European survey of cancer patients (n = 15,367) reported that 67% had anaemia at some point during the survey, and that over 60% of these patients did not receive any treatment for their anaemia. Two other surveys (the FATIGUE surveys) showed that over 75% of cancer patients experienced fatigue at least monthly, with over 30% reporting this symptom on a daily basis. Significantly, patients regarded fatigue as having a greater negative impact on their daily lives than many other cancer- or treatment-related complications, with important emotional and mental consequences including lack of self-motivation, sadness, frustration, and mental exhaustion. Indeed, fatigue was considered so debilitating, 12% of patients felt their quality of life (QoL) was so reduced that they did not wish to continue living. Anaemia is also recognised as an independent predictor of poor prognosis in cancer patients. A systematic review evaluating survival showed a 65% overall increase in the risk of mortality in cancer patients with anaemia. Increasing physicians' awareness of the importance of effectively treating anaemia in cancer patients therefore has the potential to improve prognosis as well as QoL.
Harper
Peter
P
Medical Oncology Department, Guy's Hospital, London, UK. peter.harper@kcl.ac.uk
Littlewood
Timothy
T
D000203:Activities of Daily Living; D000740:Anemia / Q000150:complications; D000747:Anemia, Hypochromic / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D017281:Cost of Illness; D004921:Erythropoietin / Q000627:therapeutic use*; D005221:Fatigue / Q000191:economics / Q000209:etiology* / Q000523:psychology*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000401:mortality / Q000628:therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D011788:Quality of Life; D011994:Recombinant Proteins; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D011994:Recombinant Proteins; D004921:Erythropoietin